Sanofi, AstraZeneca and Novartis officials told Inside Health Policy their companies continue to restrict 340B discounts available through contract pharmacies, and Eli Lilly reportedly is continuing its restrictions as well, despite a recent HHS General Counsel advisory opinion asking the drug makers to scrap their policies and restore the discounts. Attorneys representing hospitals that are suing HHS over its failure to compel the drug makers to provide the discounts via 340B contract pharmacies without restrictions sent letters to the...